Delivery Order SPE2DR25D3012-SPE2DR26F4D5C
- Not listed
- The Defense Logistics Agency awarded a $1,219.46 delivery order to AmerisourceBergen Drug Corp for Mycophenolate 500 mg tablets (100 count) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed price, competitively awarded contract—which includes no set-aside designation—represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be performed at the contractor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,576.30 in Mycophenolate 500 mg tablets (500-count units) on September 11, 2025, with an ultimate completion date of September 12, 2025. This is a firm fixed-price, non-set-aside contract with performance at the contractor's Conshohocken, Pennsylvania location. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency has awarded a delivery order valued at $2,990.28 to AmerisourceBergen Drug Corp for 100 tablets of Mycophenolate 500 mg, with an ultimate completion date of April 23, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively on April 22, 2025. The pharmaceutical product will be delivered to Conshohocken, PA, where AmerisourceBergen Drug Corp maintains its corporate office and primary operations. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,284.84 to AmerisourceBergen Drug Corp for the supply of Mycophenolate 250 mg capsules (500 count) on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-set-aside, competitively awarded contract employs firm fixed price terms and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $1,645.74 to AmerisourceBergen Drug Corp for the supply of Mycophenolate 500 mg tablets (500-count units) on September 10, 2025, with an ultimate completion date of September 11, 2025. This competitively awarded, firm fixed-price contract is unclassified and has no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- On September 29, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $2,673.03 to AmerisourceBergen Drug Corp for the supply of Mycophenolate 250 mg capsules (500 count). This firm fixed-price delivery order, with an ultimate completion date of September 30, 2025, represents a continuation of AmerisourceBergen's substantial role as a pharmaceutical supplier to the Department of Defense medical procurement system. The award was made on a competitive,...
- The Defense Logistics Agency awarded a delivery order valued at $2,743.68 to AmerisourceBergen Drug Corp for Mycophenolate 200 mg/ml suspension in 160 ml quantities. The contract, awarded July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed-price delivery order with no set-aside designation. This award falls under a competitive procurement process, reflecting AmerisourceBergen's established capability to meet federal pharmaceutical supply requirements. The...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The contract, valued at $1,187.55, is for the delivery of 500 mg mycophenolate tablets to support military treatment programs and facilities. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA, valued up to $999,999,999.00 through December 2025,...
- The Defense Logistics Agency awarded a $3,231.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Mycophenolate 200 mg/mL suspension in 160 mL quantities, with an ultimate completion date of November 12, 2025. This non-set-aside, competitively awarded contract is being performed at the company's Conshohocken, Pennsylvania location and represents a single delivery order under AmerisourceBergen's larger contract vehicle with DLA. This...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Mycophenolate 500 mg tablets. The contract has a ceiling value of $1,287.10 and a performance period extending through April 16, 2025. The award is not set aside and is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00. This IDC serves as a...
- SPE2DR25D3012Indefinite Delivery Contract
- SPE2DR25D3012-SPE2DR26F4D5CDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 500-milligram mycophenolate tablets (500 count) on December 16, 2025, with a ceiling value of $7,263.05 and ultimate completion date of December 17, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a child order under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. This delivery order falls under AmerisourceBergen's significant Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply an extensive range of medications, medical supplies, vaccines, and specialty pharmaceuticals to support military healthcare programs worldwide. Mycophenolate, an immunosuppressant medication commonly used in transplant and autoimmune disease management, represents the type of critical pharmaceutical commodity that DLA procures through this vehicle to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.3k | 12/15/25 |